Skip to content

Safety and Efficacy of Devices Used in Fetoscopic Neural Tube Defect Repair Cases

Safety and Efficacy of Devices Used in Fetoscopic Neural Tube Defect Repair Cases

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05672849
Enrollment
100
Registered
2023-01-05
Start date
2022-11-14
Completion date
2027-12-31
Last updated
2025-12-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Neural Tube Defects

Keywords

myelomeningocele, MMC, NTD, neural tube defect, spina bifida

Brief summary

The purpose of the study is to evaluate the safety and efficacy of devices used in patients undergoing fetoscopic neural tube defect repair.

Detailed description

All patients who choose to undergo fetoscopic neural tube defect repair at Texas Children's Fetal Center will be offered participation in this research study by study investigators. Description of study rationale and design and a focused interview by the study coordinator to afford potential participants a formal opportunity to examine what they have learned about the research study in the course of their evaluation and discuss how they feel about enrolling in the research study. Once the patient is deemed eligible the informed consent process will be reviewed. If patients elect to participate in the study, informed consent will be obtained, and patients provided a copy of the signed consent. Fetoscopic Procedure: The fetoscopic open neural tube defect repair procedure will be performed with the same technique in this protocol as the investigators did in the previous protocols under this IDE (NCT02230072 and NCT03794011) in terms of exteriorization of the uterus, preparation for the fetoscopic repair and repair of the open neural tube defect. This involves release of the placode, dissection of the surrounding skin, development of myofascial flaps on either side of the defect, placement of a patch to be laid on top of the placode prior to closure of the myofascial flaps, suture of the flaps over the freed placode and patch and attempted primary closure of the defect using available skin. If necessary, the surgeons will use relaxing incisions or a skin patch to provide additional mobility to the skin to be closed over the defect. If the surgeons are unable to close the skin primarily despite best fetoscopic efforts, the option of performing/completing the repair as an open procedure exists and will be offered to the subject. Follow-Up: The investigators will follow patients for the immediate post-procedure period (until they leave the OR).

Interventions

DEVICEModified Surgical Instruments/Devices (Sheaths and Irrigator)

Patients who choose to undergo fetoscopic surgery will be offered participation in this study. All patients will undergo a fetoscopic repair of the fetal open neural tube defect with the use of the modified devices in this study.

Sponsors

Baylor College of Medicine
CollaboratorOTHER
Michael A Belfort
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients who elect to undergo fetoscopic neural tube defect repair

Exclusion criteria

* Patients who do not elect to undergo fetoscopic neural tube defect repair

Design outcomes

Primary

MeasureTime frameDescription
Number of adverse eventsImmediate Post-Procedure period (until the leave the OR)Number of adverse events associated with the investigational device
Number of device defects, malfunctions, or failuresImmediate Post-Procedure period (until the leave the OR)Number of device defects, malfunctions, or failures and whether the device performed as intended.

Countries

United States

Contacts

Primary ContactMichael A Belfort, MD
belfort@bcm.edu832-826-7375
Backup ContactBecky Johnson
rj2@bcm.edu832-826-7451

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026